Incyte (INCY) PT Raised to $113 at RBC

RBC Capital analyst Simos Simeonidis reiterated an Outperform rating and boosted his price target on Incyte (NASDAQ: INCY) to $113.00 (from $106.00) following the epacadostat update at ESMO

Simeonidis commented, "Despite what we acknowledge is a small sample size, and the fact that we’ve only seen very strong evidence of its activity and safety in one tumor type (melanoma), we remain impressed by the data and are thus raising the probability of success for the drug in this indication."

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $92.11 yesterday.

You May Also Be Interested In

• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
• TD Cowen Resumes EQT Corp. (EQT) at Hold